AstraZeneca Phase III Results for HPP Therapy Presented at ASBMR

AstraZeneca presented Phase III data for efzimfotase alfa, an investigational enzyme replacement therapy for hypophosphatasia (HPP), at the American Society for Bone and Mineral Research annual meeting. The company reported that the therapy showed improvements in function, pain, and fatigue in adolescents and adults. However, the HICKORY trial did not meet its primary endpoint, which was the change in the Six-Minute Walk Test at 25 weeks.

The presentation of Phase III results for efzimfotase alfa provides insight into the commercial viability of new treatments for rare inherited conditions like HPP. While the therapy showed improvements in patient function, the failure to meet the primary statistical endpoint could impact future regulatory approval and market adoption.